Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. [electronic resource]
Producer: 20111014Description: 2099-106 p. digitalISSN:- 1460-2091
- Adult
- Alanine Transaminase -- blood
- CD4 Lymphocyte Count
- Drug Resistance, Multiple, Viral
- Endpoint Determination
- Enfuvirtide
- Female
- France
- Genotype
- HIV Envelope Protein gp41 -- therapeutic use
- HIV Fusion Inhibitors
- HIV Infections -- blood
- HIV Integrase Inhibitors -- adverse effects
- HIV-1
- Humans
- Male
- Microbial Sensitivity Tests
- Middle Aged
- Peptide Fragments -- therapeutic use
- Pilot Projects
- Prospective Studies
- Pyrrolidinones -- adverse effects
- RNA, Viral -- blood
- Raltegravir Potassium
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.